Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Enhancement of drug delivery through fibroblast activation protein–targeted near-infrared photoimmunotherapy
Seitaro Nishimura, Kazuhiro Noma, Tasuku Matsumoto, Yasushige Takeda, Tatsuya Takahashi, Hijiri Matsumoto, Kento Kawasaki, Hotaka Kawai, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Shunsuke Tanabe, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Peter L. Choyke, Hisataka Kobayashi, Toshiyoshi Fujiwara
Seitaro Nishimura, Kazuhiro Noma, Tasuku Matsumoto, Yasushige Takeda, Tatsuya Takahashi, Hijiri Matsumoto, Kento Kawasaki, Hotaka Kawai, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Shunsuke Tanabe, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Peter L. Choyke, Hisataka Kobayashi, Toshiyoshi Fujiwara
View: Text | PDF
Research Article Gastroenterology Oncology

Enhancement of drug delivery through fibroblast activation protein–targeted near-infrared photoimmunotherapy

  • Text
  • PDF
Abstract

The tumor microenvironment plays a key role in cancer progression and therapy resistance, with cancer-associated fibroblasts (CAFs) contributing to desmoplasia, extracellular matrix (ECM) remodeling, and elevated interstitial fluid pressure, all of which hinder drug delivery. We investigated fibroblast activation protein–targeted (FAP-targeted) near-infrared photoimmunotherapy (NIR-PIT) as a strategy to improve drug penetration in CAF-rich tumors. In clinical esophageal cancer samples, FAP expression strongly correlated with increased collagen I, hyaluronic acid, and microvascular collapse. CAF-rich 3D spheroids demonstrated elevated ECM deposition and significantly impaired drug uptake compared with CAF-poor models. FAP-targeted NIR-PIT selectively reduced CAFs, reduced ECM components, and restored drug permeability. In vivo, FAP-targeted NIR-PIT enhanced the accumulation of panitumumab and Abraxane in CAF-rich tumors and improved antitumor efficacy when combined with chemotherapy. These findings highlight FAP-targeted NIR-PIT as a promising therapeutic approach to remodel the tumor stroma and overcome drug resistance in desmoplastic solid tumors.

Authors

Seitaro Nishimura, Kazuhiro Noma, Tasuku Matsumoto, Yasushige Takeda, Tatsuya Takahashi, Hijiri Matsumoto, Kento Kawasaki, Hotaka Kawai, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Shunsuke Tanabe, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Peter L. Choyke, Hisataka Kobayashi, Toshiyoshi Fujiwara

×

Figure 6

Impact of FAP-targeted NIR-PIT on drug delivery in CAF-rich spheroid models.

Options: View larger image (or click on image) Download as PowerPoint
Impact of FAP-targeted NIR-PIT on drug delivery in CAF-rich spheroid mod...
CAF-rich spheroids (human TE8 cells cocultured with human FEF3 cells at a 1:1 ratio) were used throughout this figure. (A) Diagram of treatment schedule and NIR light irradiation for IHC in FAP-targeted NIR-PIT. (B) Fluorescent IHC images showing Abra-DIG distribution in control and NIR-PIT–treated CAF-rich spheroids 1 hour after treatment. DIG, red; DAPI, blue. Original magnification, ×100 (scale bars: 200 μm). (C) Quantitative analysis of Abra-DIG fluorescence intensity per area (μm2) in control and NIR-PIT–treated CAF-rich spheroids (n = 4; mean ± SEM; unpaired t test). (D) Protocol diagram for treatment schedule and NIR light irradiation in IHC. (E) Fluorescent IHC images depicting Pan-DIG distribution in control and NIR-PIT–treated CAF-rich spheroids 2 days after treatment. DIG, red; DAPI, blue. Original magnification, ×100 (scale bars: 200 μm). (F) Quantitative comparison of Pan-DIG fluorescence intensity per area (μm2) in control and NIR-PIT–treated CAF-rich spheroids (n = 4; mean ± SEM; unpaired t test). (G) Diagram of treatment schedule and NIR light irradiation protocol for flow cytometric analysis. (H) Flow cytometric analysis quantifying Pan-Alexa568 binding in control and NIR-PIT–treated CAF-rich spheroids (n = 4; mean ± SEM; unpaired t test). Statistical significance: **P < 0.01; ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts